Pyogenic Granuloma in a Patient on Gefitinib

Granuloma Piogénico em Doente a Realizar Gefitinib

António Fernandes MASSA, Ana ANTUNES, Paulo VARELA


Keywords: Granuloma, Pyogenic; Gefitinib.
Palavras-chave: Gefitinib; Granuloma Piogénico.

Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used to treat advanced non small cell lung cancer. The most frequent cutaneous side effect is pilo-sebaceous follicle inflammation. Pyogenic granuloma (PG) is less common, usually presenting in periungual location associated with paronychia, in a delayed time manner.

We report the case of a 55-year-old female with stage IIIIB pulmonary adenocarcinoma (T3N3M0) EGFR mutated, treated with gefitinib for 16 months with sustained response, with a rapidly growing and bleeding nodule on the finger, with 2 months of evolution, without trauma awareness. At objective examination an erythematous and friable nodule of 10 mm on the first phalanx of the left first finger was observed (Fig. 1). The diagnosis of PG was made and confirmed after excision, by its histological features (Fig. 2).

Although its aspect was suggestive of PG, an amelanotic melanoma or cutaneous metastasis could not be ruled out without pathologic examination.

REFERENCES